Abstracts

TRANSCRIPTOME PROFILING AND DATA MINING: PREDICTIVE GENES OF HIV DISEASE PROGRESSION

The elite controller (EC)-long term non-progressors (LTNP) represent a spontaneous model of activation of the immune system against HIV-1, maintaining high levels of CD4+ T cell counts and undetectable viral replication in the absence of antiretroviral therapy (ART). The use of transcriptome studies combined with data mining reveals potential markers of HIV disease progression. Peripheral…

SWITCH TO BICTEGRAVIR/F/TAF FROM DTG AND ABC/3TC

Bictegravir, a novel, unboosted INSTI with a high barrier to resistance and low potential for drug interactions, has been coformulated with the recommended NRTI backbone of emtricitabine and tenofovir alafenamide (B/F/TAF) as a fixed-dose combination (FDC). We report the primary Week (W) 48 efficacy and safety Phase 3 results of switching to B/F/TAF from dolutegravir…

IMPACT OF RALTEGRAVIR INTENSIFICATION OF FIRST-LINE ART ON IRIS IN THE REALITY TRIAL

Among HIV-infected adults/children with CD4<100 cells/ul initiating ART in sub-Saharan Africa, the REALITY trial (ISRCTN43622374) showed that 12-week raltegravir (RAL)-intensified quadruple therapy resulted in significantly faster VL declines through 24 weeks, but did not reduce overall mortality or WHO 3/4 events compared to standard triple-drug ART. Integrase inhibitors may replace NNRTIs in first-line ART; there…

HAIR ANTIRETROVIRAL LEVELS STRONGLY PREDICT VIROLOGIC OUTCOMES IN ACTG’S A5257 TRIAL

AIDS Clinical Trials Group (ACTG) A5257 was a three-arm study comparing atazanavir/ritonavir (ATV/r), darunavir/ritonavir (DRV/r) and raltegravir (RAL)-based regimens in naïve patients. The study showed similar rates of virologic success in all three arms, with RAL regimens better tolerated than protease inhibitor-regimens. Hair antiretroviral (ARV) levels reflect long-term exposure and have been associated with virologic…

MULTIPLE DAILY DOSES OF MK-8591 AS LOW AS 0.25 MG ARE EXPECTED TO SUPPRESS HIV

MK-8591 is a nucleoside reverse transcriptase translocation inhibitor (NRTTI) in clinical development for the treatment of HIV-1 infection. MK-8591-triphosphate (MK-8591-TP), the active phosphorylated anabolite of MK-8591, exhibits a half-life of ~78-128 hours in human peripheral blood mononuclear cell (PBMCs). MK-8591 has been assessed in a monotherapy pharmacodynamic (PD) trial in treatment-naïve HIV-1-infected subjects, where single…

CHARACTERIZATION OF THE NEUTRALIZING ANTIBODY RESPONSE IN A LINKED HIV SUPERINFECTION

HIV-superinfection (HIV-SI) occurs when an infected individual acquires a new HIV strain that is phylogenetically distinct from their existing viral population. HIV-SI provides an opportunity to examine the potential role of pre-existing HIV-specific neutralizing antibodies (NAb) in protecting against a subsequent HIV challenge. Virally unlinked HIV+ individuals in monogamous (n=15) and polygamous relationships (n=6) from…